CA-HILLSTONE-NETWORKS
7.6.2022 08:02:11 CEST | Business Wire | Press release
Hillstone Networks , a leading provider of innovative and accessible cybersecurity solutions, today announced the global availability of their simplified portfolio that delivers on cyber resilience, securing critical assets against sophisticated, multifaceted cyberattacks and an expanding attack surface.
Today’s workforce and workloads require flexibility, quality of service, and above all, protection. Security solutions need to be equally flexible and deliver on enterprise-grade cyber resilience. The Hillstone Networks solutions have evolved from a network security platform, included in the Gartner Magic Quadrant for Enterprise Firewalls for 8 consecutive years, into a robust portfolio that delivers on cyber resilience, from edge to cloud, and everything in between, to over 23,000 customers worldwide.
At RSAC 2022, in San Francisco, Hillstone will showcase its broad range of solutions across these initiatives:
- SD-WAN : Hillstone Secure SD-WAN secures today’s borderless networks with granular visibility and enforcement into all interactions across all entry points into the network, with the ability to drill further into user, device, and access behavior.
- ZTNA : Hillstone ZTNA solution secures remote access for today’s work-from-anywhere deployments, or heavily regulated industries with sensitive data that need to secure their evolving edge perimeter. Fine-grained access controls allow for precise enforcement of privileges from wherever it’s needed.
- Microsegmentation : Hillstone CloudHive protects cloud-native and cloud-based apps, for dev/ops teams who rely on app portability and microservices, and cloud service providers where multi-tenancy can be risky without segmenting or isolating network access. Support for both VMware and OpenStack provide cross-platform portability across clouds.
- CWPP : Hillstone CloudArmour protects cloud applications running in public or multiple cloud environments, integrating into existing CI/CD and DevOps environments and processes with full application stack visibility. Protect bare metal hosts, virtual machines, containers, and serverless workloads.
- NDR : Hillstone sBDS delivers continuous network monitoring with an AI-driven network detection and response platform that collects and aggregates network traffic data, applying behavioral analysis and AI/ML, and delivering insights to security teams from a single view.
- XDR : Hillstone iSource rolls up all the key activities including threat detection, investigation, response, and real-time threat hunting into a single platform and get extensive visibility across all relevant threat data from device endpoints, applications, networks, and security devices, including 3rd party devices.
“Cyber-resiliency is the infrastructure’s ability to weather a storm of relentless attacks and bounce quickly back. Cyber-resilient infrastructure transforms traditional security, which is inflexible, static, and impractical, into a modernized and agile security plan that’s adaptive, dynamic, and realistic. This is the Hillstone vision and reflected in the solutions we deliver to the market,” states Tim Liu, CTO and co-founder, Hillstone Networks.
"Today's typical IT infrastructure environment is highly disaggregated in nature and presents complex challenges with respect to security. I believe Hillstone Networks delivers a suite of AI/ML enhanced cybersecurity solutions that are designed to provide visibility, ease of deployment, and simplify ongoing management through integration into existing SecOps frameworks," states Will Townsend, Vice President & Principal Analyst, Networking & Security Practices, Moor Insights & Strategy.
About Hillstone Networks
Hillstone Networks' innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyberthreats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005278/en/
Link:
Social Media:
https://www.facebook.com/Hillstone-Networks-230976560386832/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom